Donald Küfe

50.4k citations

621 papers · 41.4k indexed · 5 hit papers · h-index 111

Impact in

Immunology top 0.05%
- Immunotherapy and Immune Responses
Oncology top 0.05%
- Cancer-related Molecular Pathways

Papers in

Hematology 96
- Chronic Myeloid Leukemia Treatments 39
Immunology 155
- Immunotherapy and Immune Responses 80

Co-authors: Surender Kharbanda Ralph R. Weichselbaum Rakesh Datta Pramod S. Pandey Dongshu Chen Dennis E. Hallahan David R. Spriggs Pierre Major
Journals: Journal of Biological Chemistry (58 papers)Blood (47 papers)Proceedings of the National Academy of Sciences (26 papers)Cancer Research (23 papers)Oncogene (22 papers)
Partner nations: United States Japan Israel

In The Last Decade

Donald Küfe

611 papers receiving 40.1k citations

Hit Papers

5 papers align trajectories log scale

Mucins in cancer: function, prognosis and therapy 2009 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Nature reviews. Cancer
1999 PubMed
1998 Nature
1997 Nature Medicine
1984 Hybridoma

Peers

Countries citing papers authored by Donald Küfe

Since Specialization

Citations

This map shows the geographic impact of Donald Küfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Küfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Küfe more than expected).

Fields of papers citing papers by Donald Küfe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Küfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Küfe. The network helps show where Donald Küfe may publish in the future.

Co-authors

The 25 scholars most cited alongside Donald Küfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Donald Küfe Line = papers co-authored together Donald Küfe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells Cancer Research ·Masayuki Hagiwara, Yota Yasumizu, Nami Yamashita, Hasan Rajabi, Atsushi Fushimi, Mark D. Long, Wei Li, Atrayee Bhattacharya, Rehan Ahmad, Mototsugu Oya, Song Liu, Donald Küfe	2020	62
2	MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells Cancer Research ·Tsuyoshi Hata, Hasan Rajabi, Hidekazu Takahashi, Yota Yasumizu, Wei Li, Caining Jin, Mark D. Long, Qiang Hu, Song Liu, Atsushi Fushimi, Nami Yamashita, Ling Kui, Deli Hong, Masaaki Yamamoto, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Mehmet Samur, Donald Küfe	2019	47
3	Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Tsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, Caining Jin, Rehan Ahmad, Yan Zhang, Ling Kui, Wei Li, Yota Yasumizu, Deli Hong, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Hidekazu Takahashi, Mehmet Samur, Donald Küfe	2019	46
4	MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells Cancer Research ·Masaaki Yamamoto, Caining Jin, Tsuyoshi Hata, Yota Yasumizu, Yan Zhang, Deli Hong, Takahiro Maeda, Masaaki Miyo, Masayuki Hiraki, Yozo Suzuki, Kunihiko Hinohara, Hasan Rajabi, Donald Küfe	2019	33
5	MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer Cancer Research ·Takahiro Maeda, Masayuki Hiraki, Caining Jin, Hasan Rajabi, Ashujit Tagde, Maroof Alam, Audrey Bouillez, Xiufeng Hu, Yozo Suzuki, Masaaki Miyo, Tsuyoshi Hata, Kunihiko Hinohara, Donald Küfe	2017	183
6	MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway Molecular Cancer Research ·Maroof Alam, Audrey Bouillez, Ashujit Tagde, Rehan Ahmad, Hasan Rajabi, Takahiro Maeda, Masayuki Hiraki, Yozo Suzuki, Donald Küfe	2016	34
7	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma Blood ·Salvia Jain, Dina Stroopinsky, Yin Li, Jacalyn Rosenblatt, Maroof Alam, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell Coll, Hasan Rajabi, Athalia R. Pyzer, Michal Bar‐Natan, Katarina Luptakova, Jon Arnason, Robin Joyce, Donald Küfe, David Avigan	2015	28
8	Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation Clinical Cancer Research ·Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Yin Li, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, Donald Küfe	2015	51
9	CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway Molecular Cancer Therapeutics ·Naoya Saito, Keiichi Sakakibara, Takuji Sato, Jonathan M. Friedman, Donald Küfe, Daniel D. VonHoff, Takumi Kawabe	2014	24
10	Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro Molecular Cancer Therapeutics ·Naoki Mine, Sayaka Yamamoto, Donald Küfe, Daniel D. Von Hoff, Takumi Kawabe	2014	10
11	MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC Molecular Cancer Research ·Maroof Alam, Rehan Ahmad, Hasan Rajabi, Donald Küfe	2014	57
12	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells Cancer Research ·Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Küfe, David Avigan	2013	41
13	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube	2012	197
14	CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin Molecular Cancer Therapeutics ·Naoki Mine, Sayaka Yamamoto, Naoya Saito, Satoshi Yamazaki, Chikako Suda, Machiyo Ishigaki, Donald Küfe, Daniel D. Von Hoff, Takumi Kawabe	2011	21
15	Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells Molecular Cancer Therapeutics ·Deepak Raina, Michio Kosugi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimamura, Geoffrey I. Shapiro, Jeffrey G. Supko, Surender Kharbanda, Donald Küfe	2011	144
16	Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells Cancer Research ·Deepak Raina, Rehan Ahmad, Maya Datt Joshi, Yin Li, Zekui Wu, Takeshi Kawano, Baldev Vasir, David Avigan, Surender Kharbanda, Donald Küfe	2009	125
17	MUC1 oncoprotein is a druggable target in human prostate cancer cells Molecular Cancer Therapeutics ·Maya Datt Joshi, Rehan Ahmad, Yin Li, Deepak Raina, Hasan Rajabi, Glenn J. Bubley, Surender Kharbanda, Donald Küfe	2009	63
18	Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O 6-Methylguanine–Induced Inhibition of p65 DNA Binding Cancer Research ·Bakhtiar Yamini, Xiaohong Yu, M. Eileen Dolan, Michael H. Wu, Donald Küfe, Ralph R. Weichselbaum	2007	33
19	MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells Cancer Research ·Takeshi Kawano, Masaki Ito, Deepak Raina, Zekui Wu, Jacalyn Rosenblatt, David Avigan, Richard M. Stone, Donald Küfe	2007	34
20	MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin Cancer Research ·Lei Huang, Dongshu Chen, Derek Liu, Yin Li, Surender Kharbanda, Donald Küfe	2005	199

About Donald Küfe

Donald Küfe is a scholar working on Hematology, Immunology, Oncology, Molecular Biology and Cancer Research, having authored 621 papers that have together received 41.4k indexed citations. Recurring topics across this work include Glycosylation and Glycoproteins Research (119 papers), Immunotherapy and Immune Responses (80 papers), Monoclonal and Polyclonal Antibodies Research (70 papers), Virus-based gene therapy research (52 papers), DNA Repair Mechanisms (48 papers), RNA modifications and cancer (41 papers), Cell death mechanisms and regulation (41 papers) and Chronic Myeloid Leukemia Treatments (39 papers). The work is most often cited by research in Immunology (10.0k citations), Oncology (12.7k citations), Molecular Biology (27.8k citations), Cancer Research (5.5k citations) and Hematology (4.0k citations). Donald Küfe has collaborated with scholars based in United States, Japan and Israel. Frequent co-authors include Surender Kharbanda, Ralph R. Weichselbaum, Rakesh Datta, Pramod S. Pandey, Dongshu Chen, Dennis E. Hallahan, David R. Spriggs, Pierre Major, Hasan Rajabi and Rehan Ahmad. Their work appears in journals such as Journal of Biological Chemistry, Blood, Proceedings of the National Academy of Sciences, Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact